Publications by authors named "Marta Bolsa-Ferruz"
Purpose: Experimental patient-specific QA (PSQA) is a time and resource-intensive process, with a poor sensitivity in detecting errors. Radiation therapy facilities aim to substitute it by means of independent dose calculation (IDC) in combination with a comprehensive beam delivery QA program. This paper reports on the commissioning of the IDC software tool myQA iON (IBA Dosimetry) for proton therapy and its clinical implementation at the MedAustron Ion Therapy Center.
View Article and Find Full Text PDFPurpose: To fully characterize the flat panel detector of the new Sphinx Compact device with scanned proton and carbon ion beams.
Materials And Methods: The Sphinx Compact is designed for daily QA in particle therapy. We tested its repeatability and dose rate dependence as well as its proportionality with an increasing number of particles and potential quenching effect.
Article Synopsis
- The study reports on the first use of the IBA Sphinx/Lynx device for daily Quality Assurance (QA) in proton and carbon ion therapies.
- Over 3 years of data collected for protons and 2 years for carbon ions focused on key QA parameters like spot size, beam range, and dose.
- The results indicate that the device effectively detects performance issues and establishes actionable tolerances, enhancing the QA process in a dual particle therapy facility.
Purpose: This paper presents a novel method for the calculation of three-dimensional (3D) Bragg-Gray water-to-detector stopping power ratio (s ) distributions for proton and carbon ion beams.
Methods: Contrary to previously published fluence-based calculations of the stopping power ratio, the s calculation method used in this work is based on the specific way GATE/Geant4 scores the energy deposition. It only requires the use of the so-called DoseActor, as available in GATE, for the calculation of the s at any point of a 3D dose distribution.
Purpose: Metal-based nanoparticles (M-NPs) have attracted great attention in nanomedicine due to their capacity to amplify and improve the tumor targeting of medical beams. However, their simple, efficient, high-yield and reproducible production remains a challenge. Currently, M-NPs are mainly synthesized by chemical methods or radiolysis using toxic reactants.
View Article and Find Full Text PDFArticle Synopsis
- AGuIX is a gadolinium-based nanoagent that enhances radiotherapy and medical imaging and is currently in clinical trials.
- This study investigates how AGuIX interacts with human serum albumin, the most common blood protein, finding that it doesn't bind to the protein but increases its stability.
- The research indicates that using AGuIX poses minimal risks to the bloodstream, and the methods developed can help assess other nano-products' effects on blood components.